ORIGINAL

Open Access

Size-dependent *in vivo/in vitro* results of homoeopathic herbal extracts

Rajesh Barve¹ and Ramesh Chaughule^{2*}

Abstract

This paper presents evidence-based results of clinical trial on the use of nanosized particles in homoeopathic *Terminalia arjuna* tincture. Dynamic light scattering technique demonstrates that homoeopathic tincture is a mixture of particles varying from micron to nanometre sizes. The process of succussion, homogenization and filtration brings down the particles of source material to nanosize as a 'top-down' process. As compared to the conventionally used micron-sized *T. arjuna* powder, the results show significant clinical improvement due to the presence of nanoparticles in tincture by the above method. Similar results were reconfirmed on experiments with bacterial cultures. From clinical trials, it has been confirmed that the dose of medicine required by the patient is significantly reduced with the reduction in particle size. No toxicity was observed even after giving medicine for more than 8 weeks. Size-dependent sensitivity of the drug can help to tackle the problem of drug resistance in bacteria.

Keywords: Lipid profile, *Terminalia arjuna*, Homoeopathy, Clinical trials, DLS method, *Holarrhena antidysenterica*, *E. coli* cultures, Zone of inhibition

Background

Holarrhena antidysenterica is a tropical plant which grows up to 5 m in height. The bark extract of this plant is used in ayurvedic and homoeopathic systems of medicine for the treatment of tropical diarrhoeas and dysentery. It belongs to Apocynaceae family. Around 30 alkaloids have been isolated from the plant, mostly from the bark. These include conessine, kurchine, kurchicine, holarrhimine, conarrhimine, conaine, conessimine, isoconessimine, conimine, holacatin and conkurchin [1]. It is a well-known drug for amoebic dysentery and other gastric disorders. It is also indicated for the treatment of diarrhoea, indigestion, flatulence and colic [2]. Homoeopathic system of medicine uses ethanolic extracts, called as mother tincture, and their dilutions (potencies). As per the Homoeopathic Pharmacopoeia of India standard, the drug strength is 1/10. Since there is no standardization criterion for the particle size of the tincture, the experimentation was carried out by changing the particle size of the tincture, and size-related effects were compared *in vitro*.

Terminalia arjuna is known over 2,000 years as good cardioprotective medicine. Many useful phytoconstituents have been isolated from *T. arjuna* which includes triterpenoids for cardiovascular properties, tannins and flavonoids for its anticancer properties and so on. The bark leaves and fruits of *T. arjuna* have been used in the indigenous system of medicine for different ailments [3]. The bark contains a very high level of flavonoids compared to other commonly used plant items. Flavonoids detected from its bark are arjunolone, flavones, bicalcin, quercetin, kempferol and pelargonidin [4-6]. Traditionally in ayurvedic medicine, *T. arjuna* powder with a dose of 1 to 2 g/day and an average powder size of about 50 µm is used for the patients. *T. arjuna* is also known to reduce lipid levels. This was verified by *in vivo* studies on 32 hyperlipidemic patients by giving them this mother tincture which has much lesser particle size.

Results and discussions

Table 1 shows the results of ten patients who took *T. arjuna* dose of 0.083 g for 8 weeks or more. The patients showed significant reduction in low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), triglyceride (TG) and total cholesterol as compared to the traditional dose of 1 to 2 g/day of *T. arjuna* powder

* Correspondence: rsctifr@yahoo.com

²Department of Chemistry, Ramnarain Ruia College, Matunga, Mumbai 400019, India

Full list of author information is available at the end of the article

Table 1 *In vivo* experiment of *T. arjuna* tincture for certain hyperlipidemic patients taking drug for 8 weeks or more

Patient number	Total cholesterol reduction (%)	HDL increase (%)	LDL reduction (%)	VLDL reduction (%)	TG reduction (%)
1	27	36	35	45	46
5	25.8	-	41.8	19	18.9
8	37	50	30	-	23.2
11	42	21	37	-	5.2
13	23	5	26.1	24.2	23.9
20	28	7.1	39	10	31.5
25	15.6	14.2	25.2	50	46.9
27	13.8	33.3	24.8	41.6	41.6
29	25.4	21	46.2	33.3	12.2
30	17.7	4.6	11.1	42.3	48.7

with a mean particle size of 50 μm available in the market. There is also an increase in high-density lipoprotein (HDL) levels by about 20% which is hardly seen in any other anti-lipid drug as HDL is cardioprotective. Figure 1 represents *Escherichia coli* M200 culture with 2.67- μm particle size of *Holarrhena* tincture on LHS plate showing no zone of inhibition. However, with 13.8-nm particle size of the same tincture on RHS plate, *E. coli* M200 gives 10 mm of zone inhibition. Figure 2 represents *E. coli* 10536 culture with *Holarrhena* tincture of particle size 2.67 μm , and Figure 3 shows *E. coli* 10536 culture with *Holarrhena* tincture having particle size of 13.8 nm.

Conclusions

This study clearly demonstrates particle size-dependent variation in the drug action. Reduction in the particle size of the drug improves the sensitivity of the drug as seen in *in vivo* experiment of *T. arjuna* drug. Reduction of particle size from 50 μm to 23 nm showed drastic reduction in dose requirement, i.e. from 1 to 2 g/day to 0.083 g/day. No toxicity was observed with this nanodose even after giving for 2 months or more.

Figure 1 *E. coli* M200 culture with *Holarrhena* tincture of 2.67 μm and 13.8 nm in size.

Figure 2 *E. coli* 10536 culture with *Holarrhena* tincture of 2.67- μm size (1 and 3), alcohol (2) and blank disc (Std).

From *in vitro* experiments with *E. coli*, it is clear that reduction of particle size of tincture improved the culture results by 15% or more. Interestingly, *E. coli* M200 showed resistance to *Holarrhena* tincture at 2.67- μm particle size but showed sensitivity at 13.8-nm particle size tincture. This phenomenon is reported for the first time and can help to reduce drug resistance problem for the patients in the future.

Methods

T. arjuna tincture manufactured by Bakson, India was used for *in vivo* clinical trials using the dynamic light scattering (DLS) system of Aimil Malvern Instruments from Baroda. Its mean particle size was 23 nm (Figure 4). *Holarrhena* tincture also manufactured by Bakson, India was used for bacterial studies. The particle size determined by DLS was found to be 2.67 μm (Figure 5). Further reduction in particle size of this tincture to 13.8 nm (Figure 6) was achieved by standard succussion, homogenization and filtration methods.

Four pathogenic strains of *E. coli* (11100, 11105, 10536, M200) were collected and inoculated in culture plates (Table 2). Nutrient agar was used as culture media. Sterile Whatman paper discs of 5-mm-diameter size were impregnated with 0.1 ml *Holarrhena antidysenterica* tincture with particle sizes of 2.67 μm and 13.8 nm, respectively. Discs

Figure 3 *E. coli* 10536 culture with *Holarrhena* tincture of 13.8-nm size (1 and 3), alcohol (2) and blank disc (Std).

Figure 4 Intensity distribution of arjuna nanoparticles using dynamic light scattering (DLS) system.

Figure 5 *Holarrhena* tincture particle size (2.67 μm) using DLS method.

Figure 6 Reduction of *Holarrhena* tincture particle size (13.8 nm).

were placed on agar media inoculated with bacterial cultures. The disc with 0.1 ml ethanol was kept as a control since tinctures contain 60% ethanol. Culture plates were incubated at 32°C for 36 h to get good bacterial colonies. Finally, zones of inhibitions were measured and compared to know the efficacy of the drug and effect of particle sizes (Figures 1, 2, 3).

All 32 hyperlipidemic patients, who were not taking any anti-lipid medicines, were randomly selected. Their vital data regarding lipid levels, diet, habits, type of work, stress level and history of present- and past-associated illnesses were noted. Every patient was given oral dose of 10 drops of *T. arjuna* tincture with water at bedtime. The calculated weight of this 23-nm particle size tincture dose is 0.083 g. Dose was given for 8 weeks and more to compare the changes in lipid levels (Table 1).

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

RB and RC carried out the *T. arjuna* and *Holarrhena antidysenterica* studies and participated in the experimental work on the *in vitro* studies of bacterial cultures. RB treated the specific patients in his clinic by giving nanodose of *T. arjuna* tincture. Both the authors provided the same contributions in this article and read and approved the final manuscript.

Acknowledgements

The authors gratefully thank Dr. Medha Shette, Dr. Vivek Athavale and Dr. Pusalkar for their help in the pathological work.

Author details

¹Department of Repertory, Virar Homoeopathic Medical College, Virar, 401305, Maharashtra, India. ²Department of Chemistry, Ramnarain Ruia College, Matunga, Mumbai 400019, India.

Received: 13 March 2013 Accepted: 4 April 2013

Published: 23 April 2013

Table 2 *E. coli* and *H. antidysenterica* tincture

	<i>Holarrhena</i> tincture zone of inhibition (mm)	
	2.67 μm	13.8 nm
<i>E. coli</i> M200	No zone	10
<i>E. coli</i> 10536	24	26
<i>E. coli</i> 11105	22	25
<i>E. coli</i> 11100	24	25

References

- Kumar, N, Singh, B, Bhandari, P, Gupta, AP, Kaul, VK: Steroidal alkaloids from *Holarrhena antidysenterica* (L) Wall. Chem. Pharm. Bull (Tokyo) **55**(6), 912 (2007)
- Singh, KP: Clinical studies of amoebiasis and giardiasis evaluating the efficacy of kutaja (*Holarrhena antidysenterica*) in *Eutamoaeta histolytica* cyst passes. Ancient Science of Life **5**, 228–231 (1986)
- Warrier, PK, Nambiar, VPK, Ramankutty, C: Indian Medicinal Plants: A Compendium of 500 Species, p. 592. Orient Blackswan, India (1996)
- Sharma, PN, Shoeb, PN, Kapil, RS, Popli, SP: Arjunolone – a new flavone from stem bark of *Terminalia arjuna*. Indian Journal of Chemistry **21B**, 263 (1982)

5. Nema, R, Jain, P, Khare, S, Pradhan, A, Gupta, A, Singh, D: Preliminary phytochemical evaluation and flavonoids quantification of *Terminalia arjuna* leaves extract. *Int. J. Pharm. Phytopharmacol. Res.* **1**(5), 283 (2012)
6. Nema, R, Jain, P, Khare, S, Pradhan, A, Gupta, A, Singh, D: Antibacterial and antifungal activity of *Terminalia arjuna* leaves extract with special reference to flavonoids. *Basic Research J. Med. Clin. Sc.* **1**(5), 63 (2012)

doi:10.1186/2193-8865-3-18

Cite this article as: Barve and Chaughule: Size-dependent *in vivo/in vitro* results of homoeopathic herbal extracts. *Journal Of Nanostructure in Chemistry* 2013 **3**:18.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com